[
 {
  "id": "COR-013",
  "date": "2026-08-04",
  "severity": "Material \u2014 our own escalation error",
  "page": "Every page quoting the approved oral semaglutide price",
  "was": "We published the approved oral semaglutide tablet at a flat $149 a month, and built a comparison around it: that four dollars separates the cheapest compounded semaglutide we captured ($145) from an FDA-approved pill.",
  "now": "Novo Nordisk's own price guide, read 4 August 2026, shows the tablet is a dose ladder. $149 covers 1.5 mg and 4 mg. Maintenance doses of 9 mg and 25 mg are $299. The $149 price on 4 mg runs only to 31 August 2026, after which it becomes $199. At a maintenance dose the approved pill is $299, not $149, so the gap against $145 compounded is about $154 a month, not four dollars.",
  "why": "This is precisely the error we document in others: quoting a starter-dose figure as though it were the price of treatment. We published a whole analysis on dose escalation and then made the mistake in our own headline comparison. The four-dollar framing has been withdrawn from every page and the ladder is published in full.",
  "source": "https://www.novocare.com/content/dam/novonordisk/novocare/redesign/pdf/Wegovy_Price_Guide.pdf",
  "evidence_id": "EV-5201"
 },
 {
  "id": "COR-012",
  "date": "2026-07-29",
  "severity": "Arithmetic query raised with the provider",
  "page": "Every page carrying NexLife plan totals",
  "was": "We published monthly rates only and did not check the provider's plan totals against them.",
  "now": "We captured all twenty-four price points with their plan totals and reconciled each against its own monthly rate. Fourteen of eighteen multi-month rows agree exactly. Four do not, three by $1 to $6 and one by $42: the semaglutide sublingual ODT 3-month plan states a $597 total against a $185 monthly rate, which multiplies to $555. $597 is the month-to-month rate times three.",
  "why": "We rank this provider first. That is exactly why its own figures get checked hardest, and why the result is published whichever way it falls. We record the monthly rate, which is what a patient is billed, and have asked for the plan total to be corrected to $555. An independent reconciliation of the same figures has since reached the same conclusion (EV-4603).",
  "source": "https://nexlife.us/pages/sublingual-semaglutide-odt",
  "evidence_id": "EV-4602"
 },
 {
  "id": "COR-011",
  "date": "2026-07-27",
  "severity": "Material update \u2014 a provider answered",
  "page": "The disclosure register and every page stating that no provider names its pharmacy",
  "was": "We recorded that NexLife stated a registration class but did not name its fulfilling pharmacy, leaving 15 of 55 rubric points locked, and we said on many pages that no provider in our dataset had named one.",
  "now": "NexLife's own plan pages name five fulfilment partners \u2014 Absolute Pharmacy, Hallandale Pharmacy, Red Rock Pharmacy, Empower Pharmacy and Strive Pharmacy \u2014 and disclose both 503A and 503B pathways. All four disclosure questions are now answered and all 55 points are unlocked.",
  "why": "A register only means something if it records an answer as readily as it records a refusal. We asked the question publicly; the provider answered it publicly; we update.",
  "source": "https://nexlife.us/pages/google-semaglutide-12-month-plan",
  "evidence_id": "EV-3501"
 },
 {
  "id": "COR-010",
  "date": "2026-07-27",
  "severity": "Moderate \u2014 wrong figure from a third party",
  "page": "Pages describing the LillyDirect 45-day refill window",
  "was": "We published that missing the 45-day refill window raises 12.5 mg to $849 a month and 15 mg to $1,049.",
  "now": "LillyDirect's own product page states the regular prices are $499 for 7.5 mg and $699 each for 10 mg, 12.5 mg and 15 mg. Corrected to the manufacturer's figures.",
  "why": "The $849 and $1,049 figures came from a third-party page. We had by then already withdrawn eleven provider figures for exactly this reason and still had not checked our own brand anchor against the manufacturer.",
  "source": "https://www.lilly.com/lillydirect/medicines/zepbound",
  "evidence_id": "EV-2702"
 },
 {
  "id": "COR-009",
  "date": "2026-07-27",
  "severity": "Serious \u2014 a second false price published",
  "page": "Every page carrying a Henry Meds monthly figure",
  "was": "We published Henry Meds compounded tirzepatide at $179 a month, described as a reported flat all-inclusive rate. Four publications report that figure.",
  "now": "Withdrawn. A source that examined the pricing states the $179 headline applies to liraglutide or a 12-month prepay rather than injectable tirzepatide, and that dose escalation adds about $100 a month per tier. Other sources give $199, about $297 introductory rising to $429-$549 at maintenance, and $1,047 for a three-month oral supply.",
  "why": "COR-008 withdrew ten figures we had taken from competitor pages. Henry Meds was not among them, because four publications agreed on $179 and agreement felt like confirmation. It is not. Four publications repeating one number is one source, not four.",
  "source": "https://healthymealsincentives.org/henry-meds-reviews/",
  "evidence_id": "EV-2401"
 },
 {
  "id": "COR-008",
  "date": "2026-07-27",
  "severity": "Serious \u2014 false prices published",
  "page": "Every ranking, comparison and cheapest page carrying a monthly figure for ten providers",
  "was": "We published monthly figures for Embody, SkinnyRx, Yucca Health, Lavender Sky Health, Fifty 410, OrderlyMeds, Trimi, TMates, Gala GLP-1 and Oak Longevity, taken from competitor comparison pages, and labelled them provider-reported. We described Embody's $99 as a flat rate.",
  "now": "Every one of those figures has been withdrawn. They were third-party claims we never confirmed at the provider's own site. The Embody figure was wrong on both counts: six sources give six different tirzepatide prices between $119 and $299, several state the low rate is promotional and rises to $299 after month one, and the $99 appears to be a semaglutide rate. A new evidence state, third-party claim, now exists and such figures cannot be ranked, summed or compared.",
  "why": "Our evidence policy exists to stop exactly this. We criticised other publications for quoting prices without their term, dose and formulation, and then republished their figures without checking any of the three. A reported status in our model means the provider reported it. We applied it to figures no provider had reported to anyone.",
  "source": "https://www.glp1clinics.org/telehealth-providers/embody",
  "evidence_id": "EV-2301"
 },
 {
  "id": "COR-007",
  "date": "2026-07-26",
  "severity": "Third-party figure \u2014 correction requested",
  "page": "Not our error. Recorded because we published the query and owe readers the resolution.",
  "was": "On 26 July 2026 we published an open query about a figure on NexLife's own page stating that SURMOUNT-1 participants lost up to 24.3% of body weight, and logged it at status pending because we could not establish which analysis produced it.",
  "now": "Resolved. No published SURMOUNT-1 analysis reports 24.3%. Lilly's own announcement states up to 22.5% for the efficacy estimand at 15 mg. The only 24.3 in the SURMOUNT-1 literature is a median time to weight plateau of 24.3 weeks. We have asked NexLife to correct the figure.",
  "why": "We publish our open queries, so we publish their resolution, including when the answer is inconvenient for the provider we feature. A query left permanently open is a smear; a query resolved is a check.",
  "source": "https://www.stocktitan.net/news/LLY/lilly-s-tirzepatide-delivered-up-to-22-5-weight-loss-in-adults-with-26h3ifcirjbn.html",
  "evidence_id": "EV-2003"
 },
 {
  "id": "COR-006",
  "date": "2026-07-26",
  "severity": "Material \u2014 conflict of interest",
  "page": "Every page emitting a reviewedBy credit, and the medical reviewers page",
  "was": "We recorded Jonathan Michael Snipes MD (NPI 1821250077) and Kim Callender FNP-BC as this publication's named medical reviewers, and emitted a reviewedBy credit naming Dr Snipes in the structured data of 526 pages.",
  "now": "Both individuals are named on RxPepsDirect's own published pages as its medical director and prescribers, and as the medical reviewers of its competing comparison of compounded tirzepatide telehealth services \u2014 a comparison in which RxPepsDirect ranks itself cheapest. RxPepsDirect sells the category this publication reviews. The reviewer credit has been suspended sitewide and the reviewedBy structured data removed pending resolution.",
  "why": "Our conflicts policy states that no clinician reviews a page about a company they work for, consult to or hold an interest in. We recorded two NPIs and never checked what those clinicians do elsewhere. That is the check the policy exists to require, and we did not run it.",
  "source": "https://www.rxpepsdirect.com/learn/best-compounded-tirzepatide-telehealth",
  "evidence_id": "EV-1601"
 },
 {
  "id": "COR-005",
  "date": "2026-07-25",
  "severity": "Material",
  "page": "All peptide pages referencing the FDA compounding advisory committee",
  "was": "We wrote that briefing documents posted 30 June 2026 recommended against adding BPC-157, TB-500 and five further peptides to the 503A list, and that the regulatory direction was toward closing the compounding route.",
  "now": "FDA staff reviewers did recommend against all seven. On 23 July 2026 the advisory committee voted the other way \u2014 8-6 with one abstention in favour of BPC-157, KPV and TB-500, and 7-5 with two abstentions for MOTS-c \u2014 overriding its own agency's scientists. The votes are non-binding and the FDA decides through formal rulemaking, which commonly takes 8 to 12 months.",
  "why": "We published the staff recommendation as though it predicted the committee outcome. It did not. The direction of travel reversed within two days of publication, and describing a live regulatory process by its most recent document is a mistake we should not repeat.",
  "source": "FDA Pharmacy Compounding Advisory Committee, 23 July 2026",
  "evidence_id": "EV-1301"
 },
 {
  "id": "COR-004",
  "date": "2026-07-24",
  "severity": "Material",
  "page": "All pages describing the tirzepatide shortage timeline",
  "was": "We wrote that the tirzepatide shortage was declared resolved in October 2024, as a single settled event.",
  "now": "FDA determined the shortage resolved on 2 October 2024. On 22 October 2024 that decision was remanded to the agency for reevaluation as part of litigation. On 5 March 2025 a district court denied the plaintiffs' preliminary injunction in Outsourcing Facilities Association v. FDA. Some sources date the resolution to December 2024 for that reason.",
  "why": "We compressed a contested twelve-month sequence into one date. The litigation is material context for anyone assessing how settled the current regulatory position is.",
  "source": "FDA drug shortage record",
  "evidence_id": "EV-0805"
 },
 {
  "id": "COR-003",
  "date": "2026-07-24",
  "severity": "Material",
  "page": "All pages showing a tirzepatide titration schedule",
  "was": "We published a fixed week-by-week escalation calendar: 2.5 mg for weeks 1\u20134, 5 mg for weeks 5\u20138, 7.5 mg for weeks 9\u201312, and so on through 15 mg by week 21.",
  "now": "The Zepbound label directs 2.5 mg once weekly for 4 weeks, an increase to 5 mg, then increases in 2.5 mg increments no sooner than every 4 weeks based on tolerability and response, to a maximum of 15 mg. It names 5, 10 and 15 mg as the recommended maintenance dosages; 7.5 and 12.5 mg are titration steps.",
  "why": "We had taken the schedule from a secondary summary rather than the label. Presenting a minimum interval as a calendar implies escalation is automatic. On a page about dosing, that is the wrong impression to leave.",
  "source": "ZEPBOUND US Prescribing Information",
  "evidence_id": "EV-0701"
 },
 {
  "id": "COR-002",
  "date": "2026-07-24",
  "severity": "Material",
  "page": "All pharmacy verification pages referencing 503B facilities",
  "was": "We wrote that 503B outsourcing facilities must comply with CGMP, in a context implying that registration demonstrated compliance.",
  "now": "CGMP compliance is a legal requirement under section 503B. FDA states separately that registration means only that the agency received the required information \u2014 it does not mean the facility is making FDA-approved drugs, and it does not mean it is in compliance with CGMP.",
  "why": "Our wording let a legal requirement carry the weight of a verified fact. The useful question is whether a facility has been inspected and what the inspection found.",
  "source": "FDA \u2014 Questions and Answers: Outsourcing Facility Registration",
  "evidence_id": "EV-0601"
 },
 {
  "id": "COR-001",
  "date": "2026-07-24",
  "severity": "Material",
  "page": "All pages comparing the $149 FDA-approved oral options against compounded programmes",
  "was": "We reported that the cheapest FDA-approved GLP-1 is now $149 a month and undercuts most of the compounded market, without stating the efficacy of the products being compared.",
  "now": "The same pages now carry the efficacy ladder. Orforglipron reported approximately 11\u201312.4% mean reduction in ATTAIN-1 and oral semaglutide 13.6\u201316.6% in OASIS 4, against about 20.9% for tirzepatide 15 mg in SURMOUNT-1. Both $149 options are the least effective approved products.",
  "why": "The price statement was accurate and the comparison was incomplete. Comparing a roughly 12% drug with a roughly 21% drug on price alone is the error this publication exists to catch.",
  "source": "ATTAIN-1, OASIS 4 and SURMOUNT-1",
  "evidence_id": "EV-0113"
 }
]